June 26, 2017. This is no joke. The Congressional Budget Office’s report only makes it clearer that the Senate health bill will not result in better health care for Americans.
Read More »We’re Speaking Out on Health Issues
NCHR scientists and health policy experts provide written and oral statements on a wide range of topics.
Here are many of the ways we have been Speaking Out on Health Policy Issues for the last few years. Whether the topic is legislation intended to cure diseases, proposed bans on BPA or other chemicals that disrupt your hormones, the importance of including women, people of color, and patients over 65 in clinical trials, or many other topics, you’ll gain a better understanding of our evidence-based analyses by reading these letters, statements, and testimony.
Here are the ways we have been Speaking out on Medical Treatments and Products, such as prescription drugs and medical devices that the FDA is considering approving, or is considering taking off the market because of serious risks. Whether the topic is Chantix, Addyi, Yaz, Essure, or medical products you’ve never heard of, you can find out more about what is known and not known about the safety and effectiveness of a wide range of products by looking through this section of our website.
Here are our Statements and Positions on issues that affect you.
NCHR Comments on Adverse Events Program for Medical Devices, Medical Product Safety Network (“MedSun”)
June 23, 2017. The FDA must improve post-market surveillance of medical devices, and MedSun should be part of that effort.
Read More »NCHR Statement on the Better Care Reconciliation Act of 2017
June 25, 2017. The Better Care Reconciliation Act of 2017 will result in much worse, not better, health care for Americans.
Read More »NCHR Comment on the USPSTF’s Draft Recommendations for Adolescent Idiopathic Scoliosis: Screening
June 22, 2017. We agree with the USPSTF’s assessment that there is inadequate evidence to support screening for adolescent idiopathic scoliosis. However, we are concerned that the change of grade from a “D” to “I” will be interpreted as if there is now more evidence to support screening instead of less confidence in the data surrounding its use.
Read More »NCHR Testimony at FDA Meeting on Pediatric Cancer Drugs
June 21, 2017. Drug efficacy is a complex issue for children with chronic and/or rare diseases like the cancers discussed here. We commend the FDA and this committee for providing an open discussion focused on the best ways to test these five new drugs in pediatric populations. This marks a positive effort to help ensure that drugs are safe and effective for everyone for whom they are prescribed, particularly when the cost of these drugs can be so high.
Read More »